PURPOSE: Increased expression of transforming growth factor-β2 (TGF-β2) is reported in the conjunctiva of dry eye patients with no increase of anti-inflammatory activity of TGF-β2. Our aim was to compare the expression of molecules involved in TGF-β2 activation, thrombospondin-1 (TSP-1) and CD36, during murine and human conjunctival inflammation. METHODS: Human conjunctival tissue from cadaveric donors, human conjunctival epithelial primary cells and fibroblasts, and murine conjunctivas were immunostained for TSP-1, CD36, or TGF-β2. Inflamed conjunctival tissues were obtained from C57BL/6 wild-type (WT) mice induced to develop experimental dry eye (EDE) with 10 days of desiccating conditions and scopolamine injections and TSP-1-deficient (TSP1(-/-)) mice, which spontaneously develop Sjögren's syndrome-associated conjunctival inflammation with age. Immunostaining intensities were compared using ImageJ software. Cultures of human conjunctival fibroblasts were stimulated with IL-1β and both secreted protein and message levels of TSP-1, CD36, and TGF-β2 were analyzed. RESULTS: TSP-1 and CD36 were detectable in human and murine conjunctival tissues as well as primary conjunctival epithelial cells and fibroblasts. Increased conjunctival immunostaining of TGF-β2 and reduced CD36 were detected in EDE mice compared with WT mice. Interestingly, increased TGF-β2 and CD36 conjunctival immunostaining was detected in TSP1(-/-) mice. The expression of TSP-1 and CD36 was downregulated in IL-1β-stimulated conjunctival fibroblasts at both the protein and message level, while active TGF-β2 was undetected. CONCLUSIONS: The absence or reduced expression of either of the molecules involved in TGF-β2 activation supports proinflammatory conditions in the conjunctiva. Changes in TSP-1 and CD36 may serve as potential biomarkers of conjunctival inflammation.
PURPOSE: Increased expression of transforming growth factor-β2 (TGF-β2) is reported in the conjunctiva of dry eyepatients with no increase of anti-inflammatory activity of TGF-β2. Our aim was to compare the expression of molecules involved in TGF-β2 activation, thrombospondin-1 (TSP-1) and CD36, during murine and humanconjunctival inflammation. METHODS:Human conjunctival tissue from cadaveric donors, human conjunctival epithelial primary cells and fibroblasts, and murine conjunctivas were immunostained for TSP-1, CD36, or TGF-β2. Inflamed conjunctival tissues were obtained from C57BL/6 wild-type (WT) mice induced to develop experimental dry eye (EDE) with 10 days of desiccating conditions and scopolamine injections and TSP-1-deficient (TSP1(-/-)) mice, which spontaneously develop Sjögren's syndrome-associated conjunctival inflammation with age. Immunostaining intensities were compared using ImageJ software. Cultures of human conjunctival fibroblasts were stimulated with IL-1β and both secreted protein and message levels of TSP-1, CD36, and TGF-β2 were analyzed. RESULTS:TSP-1 and CD36 were detectable in human and murine conjunctival tissues as well as primary conjunctival epithelial cells and fibroblasts. Increased conjunctival immunostaining of TGF-β2 and reduced CD36 were detected in EDE mice compared with WT mice. Interestingly, increased TGF-β2 and CD36 conjunctival immunostaining was detected in TSP1(-/-) mice. The expression of TSP-1 and CD36 was downregulated in IL-1β-stimulated conjunctival fibroblasts at both the protein and message level, while active TGF-β2 was undetected. CONCLUSIONS: The absence or reduced expression of either of the molecules involved in TGF-β2 activation supports proinflammatory conditions in the conjunctiva. Changes in TSP-1 and CD36 may serve as potential biomarkers of conjunctival inflammation.
Authors: Dilek Dursun; Min Wang; Dagoberto Monroy; De-Quan Li; Balakrishna L Lokeshwar; Michael Stern; Stephen C Pflugfelder Journal: Adv Exp Med Biol Date: 2002 Impact factor: 2.622
Authors: M Janabi; S Yamashita; K Hirano; N Sakai; H Hiraoka; K Matsumoto; Z Zhang; S Nozaki; Y Matsuzawa Journal: Arterioscler Thromb Vasc Biol Date: 2000-08 Impact factor: 8.311
Authors: Y Diebold; M Calonge; N Fernández; M C Lázaro; S Callejo; J M Herreras; J C Pastor Journal: Graefes Arch Clin Exp Ophthalmol Date: 1997-05 Impact factor: 3.117
Authors: Hong Wei Chu; Silvana Balzar; Gregory J Seedorf; Jay Y Westcott; John B Trudeau; Phil Silkoff; Sally E Wenzel Journal: Am J Pathol Date: 2004-10 Impact factor: 4.307
Authors: William Foulsham; Thomas H Dohlman; Sharad K Mittal; Yukako Taketani; Rohan Bir Singh; Sharmila Masli; Reza Dana Journal: Ocul Surf Date: 2019-06-05 Impact factor: 5.033
Authors: Laura Soriano-Romaní; Fayaz A Mir; Niharika Singh; Ian Chin; Ali Hafezi-Moghadam; Sharmila Masli Journal: Int J Mol Sci Date: 2022-05-20 Impact factor: 6.208
Authors: Ivan Fernandez-Bueno; Ricardo Usategui-Martín; José Carlos Pastor; Cristina Andrés-Iglesias Journal: Transl Vis Sci Technol Date: 2021-12-01 Impact factor: 3.283
Authors: Ricardo Usategui-Martín; Kevin Puertas-Neyra; María-Teresa García-Gutiérrez; Manuel Fuentes; José Carlos Pastor; Ivan Fernandez-Bueno Journal: Mol Ther Methods Clin Dev Date: 2020-05-13 Impact factor: 6.698